Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 2
1963 3
1964 1
1965 2
1971 1
1972 4
1973 14
1974 9
1975 16
1976 12
1977 17
1978 24
1979 14
1980 19
1981 22
1982 23
1983 15
1984 17
1985 16
1986 17
1987 16
1988 10
1989 21
1990 17
1991 20
1992 21
1993 18
1994 20
1995 17
1996 8
1997 19
1998 20
1999 19
2000 20
2001 24
2002 15
2003 13
2004 18
2005 15
2006 28
2007 36
2008 29
2009 30
2010 32
2011 40
2012 51
2013 40
2014 48
2015 43
2016 49
2017 46
2018 58
2019 58
2020 63
2021 68
2022 66
2023 60
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

1,360 results

Results by year

Filters applied: . Clear all
Page 1
New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M. Puglisi S, et al. Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101415. doi: 10.1016/j.beem.2020.101415. Epub 2020 Mar 5. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32179008 Free article. Review.
The aim of adjuvant mitotane therapy is to reduce the risk of ACC recurrence following surgical removal of the tumor. ...In this clinical setting, mitotane is used in association with chemotherapy to treat the more aggressive forms, while mitotane monotherapy …
The aim of adjuvant mitotane therapy is to reduce the risk of ACC recurrence following surgical removal of the tumor. ...In this clin …
Mitotane.
[No authors listed] [No authors listed] 2020 Feb 19. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Feb 19. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643764 Free Books & Documents. Review.
Mitotane is a unique antineoplastic agent used solely in the therapy of metastatic, unresectable adrenocortical carcinoma. Mitotane has been associated with a high rate of serum enzyme elevation during therapy, but has had limited clinical use and has not been linke …
Mitotane is a unique antineoplastic agent used solely in the therapy of metastatic, unresectable adrenocortical carcinoma. Mitotan …
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.
Steenaard RV, Rutjens M, Ettaieb MHT, van Noesel MM, Haak HR. Steenaard RV, et al. Discov Oncol. 2022 Apr 18;13(1):25. doi: 10.1007/s12672-022-00486-1. Discov Oncol. 2022. PMID: 35435506 Free PMC article. Review.
Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection. However, little is known about the impact of EDP-mitotane in children. ...Combined wit …
Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cispla …
Understanding mitotane mode of action.
Waszut U, Szyszka P, Dworakowska D. Waszut U, et al. J Physiol Pharmacol. 2017 Feb;68(1):13-26. J Physiol Pharmacol. 2017. PMID: 28456766 Free article. Review.
Adrenocortical carcinoma is a rare disease with poor prognosis. Mitotane is the most effective agent in post-operative treatment (or when inoperable). ...We consider features of the adrenal cortex that might explain mitotane selectivity, and review effects on non-ad …
Adrenocortical carcinoma is a rare disease with poor prognosis. Mitotane is the most effective agent in post-operative treatment (or …
Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Corso CR, et al. Br J Clin Pharmacol. 2021 Jul;87(7):2698-2710. doi: 10.1111/bcp.14721. Epub 2021 Feb 2. Br J Clin Pharmacol. 2021. PMID: 33382119 Free article. Review.
Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). ...Therefore, the aim of this review was to summarize the chemistry, pharmacokinetics and pharmacodynamics, and therapeutic and toxic effects of …
Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). ...Th …
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review.
Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M. Bianchini M, et al. Cancers (Basel). 2021 Oct 5;13(19):5001. doi: 10.3390/cancers13195001. Cancers (Basel). 2021. PMID: 34638485 Free PMC article. Review.
Despite the pivotal role of mitotane in adrenocortical carcinoma (ACC) management, data on the endocrine toxicities of this treatment are lacking. ...Most of these side effects appear to be reversible after mitotane discontinuation. We finally suggest an algorithm t …
Despite the pivotal role of mitotane in adrenocortical carcinoma (ACC) management, data on the endocrine toxicities of this treatment …
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Haider MS, Ahmad T, Groll J, Scherf-Clavel O, Kroiss M, Luxenhofer R. Haider MS, et al. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5. Epub 2021 Jul 21. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34287806 Free PMC article. Review.
Moreover, we present recent efforts to improve mitotane formulations. Their success has been limited, and we therefore propose an injectable mitotane formulation instead of oral administration, which could bypass many of the main issues associated with high-dose ora …
Moreover, we present recent efforts to improve mitotane formulations. Their success has been limited, and we therefore propose an inj …
Mitotane for adrenocortical carcinoma treatment.
Hahner S, Fassnacht M. Hahner S, et al. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. Curr Opin Investig Drugs. 2005. PMID: 15898346 Review.
It is known that metabolic activation is essential for the adrenolytic activity of mitotane. Most published clinical reports of mitotane use are retrospective analyses of small numbers of patients, however, the collective findings of these studies indicate that m …
It is known that metabolic activation is essential for the adrenolytic activity of mitotane. Most published clinical reports of mi …
Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.
Lo Iacono M, Puglisi S, Perotti P, Saba L, Petiti J, Giachino C, Reimondo G, Terzolo M. Lo Iacono M, et al. Cancers (Basel). 2021 Oct 20;13(21):5255. doi: 10.3390/cancers13215255. Cancers (Basel). 2021. PMID: 34771418 Free PMC article. Review.
Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma and is increasingly used for postoperative adjuvant therapy. ...Although it is known that mitotane destroys the adrenal cortex and impairs steroidogenesis, its exact mechanism …
Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma and is increasingly used for postoperative …
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Warde KM, Lim YJ, Ribes Martinez E, Beuschlein F, O'Shea P, Hantel C, Dennedy MC. Warde KM, et al. Endocrinology. 2022 Sep 1;163(9):bqac102. doi: 10.1210/endocr/bqac102. Endocrinology. 2022. PMID: 35797592 Free PMC article.
METHODOLOGY: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using specific BODIPY dyes. ...Decreased lipid droplets were associated with increased lipolysis in H295R and in MUC-1 at toxic mitotane con …
METHODOLOGY: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using s …
1,360 results